Atherosclerotic plaque regression - The role of statin therapy

Drugs of Today

Volumn 46, Issue 8, 2010, Pages 601-608

  Sastry, P ^a   Kaski, J C ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATENOLOL; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETC 216; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; NITRIC OXIDE; OLMESARTAN; PHOSPHATIDYLCHOLINE; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTERIAL WALL THICKNESS; ATHEROGENESIS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; B SCAN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY OBSTRUCTION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DRUG DOSE COMPARISON; DRUG INDUCED HEADACHE; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; GASTROINTESTINAL DISEASE; GENE ACTIVATION; HUMAN; HYPERTENSION; INFLAMMATION; INTRAVASCULAR ULTRASOUND; ISCHEMIA; LOW DRUG DOSE; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOGENICITY; ANIMAL; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; PATHOLOGY; TREATMENT OUTCOME;

ANIMALS; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; TREATMENT OUTCOME;

EID: 79952110879     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.8.1516983     Document Type: Review

References (44)

1. Hansson, G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352(16): 1685-95.
2. Halvorsen, B., Otterdal, K., Dahl, T.B., Skjelland, M., Gullestad, L., Øie, E., Aukrust, P. Atherosclerotic plaque stability-What determines the fate of a plaque? Prog Cardiovasc Dis 2008, 51(3): 183-94.
3. Shmilovich, H., Cheng, V, Tamarappoo, B., Dey, D., Slomka, P., Berman, D. Adverse characteristics in coronary arterial plaques causing severe stenoses on coronary computed tomography angiography (CCTA) predict inducible ischemia on myocardial perfusion imaging (MPI). J Nucl Med 2010, 51(Suppl. 2): 430.
4. Armstrong, M.L. Evidence of regression of atherosclerosis in primates and man. Postgrad Med J 1976, 52(609): 456-61.
5. Friedman, M.S., Beyrs, O., Rosenman, R.H. Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion. Proc Soc Exp Biol Med 1957, 95(3): 586-8.
6. Miyazaki, A., Sakuma, S., Morikawa, W. et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995, 15(11): 1882-8.
7. Reis, E.D., Li, J., Fayad, Z.A. et al. Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model. J Vasc Surg 2001, 34(3): 541-7. (Pubitemid 33661190)
8. Rong, J.X., Li, J., Reis, E.D. et al. Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content. Circulation 2001, 104(20): 2447-52. (Pubitemid 33108379)
9. Klein, L.W. Atherosclerosis regression, vascular remodeling, and plaque stabilization. J Am Coll Cardiol 2007, 49(2): 271-3.
10. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344(8934): 1383-9.
11. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomized placebo-controlled trial. Lancet 2002, 360(9326): 7-22.
12. Williams, K.J., Feig, J.E., Fisher, E.A. Rapid regression of atherosclerosis: Insights from the clinical and experimental literature. Nat Clin Pract Cardiovasc Med 2008, 5(2): 91-102. (Pubitemid 351168064)
13. Alsafwah, S., Ramanathan, K.B. Can we cause regression of coronary arteries? Am J Med Sci 2008, 335(5): 368-74.
14. Chambless, L.E., Heiss, G., Folsom, A.R., Rosamond, W., Szklo, M., Sharrett, A.R., Clegg, L.X. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: The Atherosclerosis Risk in Communities (ARIC) Study, 1987-1993. Am J Epidemiol 1997, 146(6): 483-94.
15. Hodis, H.N., Mack, W.J., LaBree, L., Selzer, R.H., Liu, C.R., Liu, C.H., Azen, S.P. The role of carotid arterial intima-media thickness in predicting clinical coronary events. Ann Intern Med 1998, 128(4): 262-9. (Pubitemid 28090756)
16. Smilde, T.J., van Wissen, S., Wollersheim, H. et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia ((ASAP): A prospective, randomized, double-blind trial. Lancet 2001, 357(9256): 577-81. (Pubitemid 32179609)
17. Jang, I.K., Bouma, B.E., Kang, D.H. et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: Comparison with intravascular ultrasound. J Am Coll Cardiol 2002, 39(4): 604-9. (Pubitemid 34158155)
18. Aoki, J., Rodríguez-Granillo, G.A., Serruys, P.W. Emergent strategies in interventional cardiology. Rev Esp Cardiol 2005, 58(8): 962-73.
19. Nair, A., Kuban, B.D., Tuzcu, E.M., Schoenhagen, P., Nissen, S.E., Vince, D.G. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002, 106(17): 2200-6. (Pubitemid 35222213)
20. Schaar, J.A., de Korte, C.L., Mastik, F. et al. Intravascular palpography for high-risk vulnerable plaque assessment. Herz 2003, 28(6): 488-95. (Pubitemid 37254674)
21. Nissen, S.E., Tuzcu, E.M., Schoenhagen, P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004, 291(9): 1071-80.
22. Nissen, S.E., Nicholls, S.J., Sipahi, I. et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006, 295(13): 1556-65.
23. Rodriguez-Granillo, CA., Agostoni, P., Garcia-Garcia, H.M. et al. Meta-analysis of the studies assessing temporal changes in coronary plaque volume using intravascular ultrasound. Am J Cardiol 2007, 99(1): 5-10. (Pubitemid 44969333)
24. Nicholls, S.J., Tuzcu, E.M., Sipahi, I. et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007, 297(5): 499-508.
25. Underhill, H.R., Yuan, C., Zhao, X.Q. et al. Effect ofrosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: A high-resolution magnetic resonance imaging trial. Am Heart J 2008, 155(3): 584.e1-8.
26. Yonemura, A., Momiyama, Y., Fayad, Z.A. et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J Am Coll Cardiol 2005, 45(5): 733-42. (Pubitemid 40278972)
27. Lima, J.A., Desai, M.Y., Steen, H., Warren, W.P., Gautam, S., Lai, S. Statin-induced cholesterol lowering and plaque regression after 6 months of magnetic resonance imaging-monitored therapy. Circulation 2004, 110(16): 2336-41. (Pubitemid 39407336)
28. Crisby, M., Nordin-Fredriksson, G., Shah, P.K., Yano, J., Zhu, J., Nilsson, J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: Implications for plaque stabilization. Circulation 2001, 103(7): 926-33. (Pubitemid 32183796)
29. Corti, R., Fuster, V., Fayad, Z.A. et al. Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: Two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation 2002, 106(23): 2884-7. (Pubitemid 35424736)
30. Tang, T.Y., Howarth, S.P., Miller, S.R. et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 2009, 53(22): 2039-50.
31. Mintz, G.S., Maehara, A. Serial intravascular assessment of atherosclerosis progression and regression. Circulation 2009, 73(9): 1557-60.
32. Cannon, C.P., Braunwald, E., McCabe, C.H. et al. Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350(15): 1495-504.
33. Pedersen, T.R., Faergeman, O., Kastelein, J.J. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005, 294(19): 2437-45. (Pubitemid 41627921)
34. Brewer, H.B. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am J Cardiol 2003, 92(4B): 23K-9K.
35. Brown, B.G., Zhao, X.Q., Chait, A. et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001, 345(22): 1583-92. (Pubitemid 33126837)
36. Taylor, A.J., Sullenberger, L.E., Lee, H.J., Lee, J.K., Grace, K.A. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004, 110(23): 3512-7.
37. Nissen, S.E., Tsunoda, T., Tuzcu, E.M. et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: A randomized controlled trial. JAMA 2003, 290(17): 2292-300. (Pubitemid 37430562)
38. Waksman, R., Torguson, R., Kent, K. et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 2010, 55(24): 2727-35.
39. Miyazaki, M., Sakonjo, H., Takai, S. Anti-atherosclerotic effects of an angiotensin converting enzyme inhibitor and an angiotensin II antagonist in Cynomolgus monkeys fed a high-cholesterol diet. Br J Pharmacol 1999, 128(3): 523-9. (Pubitemid 29504739)
40. Stumpe, K.O., Agabiti-Rosei, E., Zielinski, T. et al. Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis 2007, 1(2): 97-106.
41. Schmieder, R.E., Hilgers, K.F., Schlaich, M.P., Schmidt, B.M. Renin-angiotensin system and cardiovascular risk. Lancet 2007, 369(9568): 1208-19. (Pubitemid 46527856)
42. Tani, S., Nagao, K., Anazawa, T. et al. Relation of change in apolipoprotein B/apolipoprotein A-I ratio to coronary plaque regression after pravastatin treatment in patients with coronary artery disease. Am J Cardiol 2010, 105(2): 144-8.
43. Ridker, P.M., Danielson, E., Fonseca, F.A. et al. JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008, 359(21): 2195-207.
44. Ortego, M., Bustos, C., Hernández-Presa, M.A., Tuñón, J., Díaz, C., Hernández, G., Egido, J. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147(2): 253-61. (Pubitemid 29512257)